尼可地尔联合卡维地洛治疗冠心病心肌缺血的临床效果
|
摘要
目的探究尼可地尔联合卡维地洛治疗冠心病心肌缺血的临床效果。方法选取2018年1月至2018年8月我院收治的冠心病心肌缺血患者74例,依入院顺序将其分为常规组和联合组,每组37例。常规组患者行常规治疗,联合组患者在常规治疗基础上使用尼可地尔联合卡维地洛治疗。比较两组的治疗效果。结果治疗后,两组体力负荷时间、心肌缺血阈功率及心肌缺血总负荷均明显改善,且联合组的体力负荷时间、心肌缺血阈功率高于常规组,心肌缺血总负荷低于常规组(P<0.05);两组SAQ各因子评分及总分均升高,且联合组高于常规组(P<0.05);两组患者的LVEF均升高,且联合组高于常规组(P<0.05);两组EDV和ESV均降低,且联合组低于常规组(P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论冠心病心肌缺血患者应用尼可地尔联合卡维地洛治疗,不仅可缓解患者的心肌缺血和心绞痛发作,还可改善患者的心功能,且不良反应少,效果显著。
Objective To explore the clinical effect of nicorandil combined with carvedilol in the treatment of myocardial ischemia of coronary heart disease. Methods A total of 74 patients with myocardial ischemia of coronary heart disease admitted in our hospital from January 2018 to August 2018 were selected and divided into conventional group and combined group according to the order of admission, with 37 cases in each group. The conventional group was given conventional treatment, while the combined group was given nicorandil combined with carvedilol on the basis of the conventional group. The therapeutic effects of the two groups were compared. Results After treatment, the physical load time, myocardial ischemic threshold power and total myocardial ischemic load of the two groups improved significantly, and the physical load time and myocardial ischemic threshold power in the combined group were higher than those in the conventional group, and the total myocardial ischemic load was lower than that in the conventional group(P <0.05); the scores of each factor and total score of SAQ of the two groups increased, and those in the combined group were higher than the conventional group(P<0.05); the LVEF of both groups increased, and that in the combined group was higher than the conventional group(P<0.05); the EDV and ESV of both groups decreased, and those in the combined group were lower than the conventional group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Nicorandil combined with carvedilol can not only alleviate the myocardial ischemia and attack of angina pectoris, but also improve the cardiac function of patients with myocardial ischemia of coronary heart disease, with fewer adverse reactions and remarkable effect.
Objective To explore the clinical effect of nicorandil combined with carvedilol in the treatment of myocardial ischemia of coronary heart disease. Methods A total of 74 patients with myocardial ischemia of coronary heart disease admitted in our hospital from January 2018 to August 2018 were selected and divided into conventional group and combined group according to the order of admission, with 37 cases in each group. The conventional group was given conventional treatment, while the combined group was given nicorandil combined with carvedilol on the basis of the conventional group. The therapeutic effects of the two groups were compared. Results After treatment, the physical load time, myocardial ischemic threshold power and total myocardial ischemic load of the two groups improved significantly, and the physical load time and myocardial ischemic threshold power in the combined group were higher than those in the conventional group, and the total myocardial ischemic load was lower than that in the conventional group(P <0.05); the scores of each factor and total score of SAQ of the two groups increased, and those in the combined group were higher than the conventional group(P<0.05); the LVEF of both groups increased, and that in the combined group was higher than the conventional group(P<0.05); the EDV and ESV of both groups decreased, and those in the combined group were lower than the conventional group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Nicorandil combined with carvedilol can not only alleviate the myocardial ischemia and attack of angina pectoris, but also improve the cardiac function of patients with myocardial ischemia of coronary heart disease, with fewer adverse reactions and remarkable effect.
引文
[1]田杰,卢建刚,曾秋蓉,等.冠状动脉支架置入术对老年冠心病患者心肌纤维化和左心功能的影响[J].中华老年医学杂志,2015,34(1):23-26.
[2]胡文超,曹丰.无创血流储备分数测定对冠心病患者心肌缺血功能评估的临床进展[J].中华老年多器官疾病杂志,2018,17(2):145-149.
[3]李艳芳,牛青英,王俊莉.个体化有氧运动对高龄冠心病患者心功能、心率恢复及生活质量的影响[J].中华物理医学与康复杂志,2016,38(1):39-42.
[4]何滨,李秋波,许丹,李有田.佰塞通注射液治疗老年冠心病心肌缺血的疗效及对血液流变学的影响[J].中国老年学杂志,2014,34(12):3459-3460.
[5]陈蕾.风心病1号方联合卡维地洛、依那普利治疗风湿性心脏病心力衰竭的疗效及对Th17细胞轴相关细胞因子的影响[J].现代中西医结合杂志,2018,27(23):2532-2535.
[6]洪梅花,柏颖,童素梅.家庭关怀对急性心肌梗死恢复期患者护理干预效果的影响[J].中华现代护理杂志,2013,19(11):1249-1252.
[7]丁平,王丽军,方学奇.尼可地尔治疗合并2型糖尿病的冠心病患者PCI术后心绞痛的疗效观察[J].中国循证心血管医学杂志,2017,9(9):1080-1082.
[8]崔爽.当归补血汤联合卡维地洛治疗心肌缺血疗效观察[J].中药药理与临床,2017,33(2):197-199.
[9]姚朝阳.冠心病患者应用尼可地尔联合阿托伐他汀及健康教育的效果研究[J].河北医药,2017,39(1):72-74.
[10]姚素萍.卡维地洛辅助治疗急性心肌梗死性心力衰竭的临床效果分析[J].中国处方药,2018,16(4):76-77.
[2]胡文超,曹丰.无创血流储备分数测定对冠心病患者心肌缺血功能评估的临床进展[J].中华老年多器官疾病杂志,2018,17(2):145-149.
[3]李艳芳,牛青英,王俊莉.个体化有氧运动对高龄冠心病患者心功能、心率恢复及生活质量的影响[J].中华物理医学与康复杂志,2016,38(1):39-42.
[4]何滨,李秋波,许丹,李有田.佰塞通注射液治疗老年冠心病心肌缺血的疗效及对血液流变学的影响[J].中国老年学杂志,2014,34(12):3459-3460.
[5]陈蕾.风心病1号方联合卡维地洛、依那普利治疗风湿性心脏病心力衰竭的疗效及对Th17细胞轴相关细胞因子的影响[J].现代中西医结合杂志,2018,27(23):2532-2535.
[6]洪梅花,柏颖,童素梅.家庭关怀对急性心肌梗死恢复期患者护理干预效果的影响[J].中华现代护理杂志,2013,19(11):1249-1252.
[7]丁平,王丽军,方学奇.尼可地尔治疗合并2型糖尿病的冠心病患者PCI术后心绞痛的疗效观察[J].中国循证心血管医学杂志,2017,9(9):1080-1082.
[8]崔爽.当归补血汤联合卡维地洛治疗心肌缺血疗效观察[J].中药药理与临床,2017,33(2):197-199.
[9]姚朝阳.冠心病患者应用尼可地尔联合阿托伐他汀及健康教育的效果研究[J].河北医药,2017,39(1):72-74.
[10]姚素萍.卡维地洛辅助治疗急性心肌梗死性心力衰竭的临床效果分析[J].中国处方药,2018,16(4):76-77.